Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 14/20 | 0.58 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.58 |
| ▸ | HDAC3 | O15379 | 8/20 | 0.57 |
| ▸ | HDAC2 | Q92769 | 8/20 | 0.57 |
| ▸ | HDAC4 | P56524 | 7/20 | 0.57 |
| ▸ | HDAC7 | Q8WUI4 | 7/20 | 0.57 |
| ▸ | HDAC10 | Q969S8 | 7/20 | 0.57 |
| ▸ | HDAC11 | Q96DB2 | 7/20 | 0.57 |
| ▸ | HDAC8 | Q9BY41 | 7/20 | 0.57 |
| ▸ | HDAC6 | Q9UBN7 | 7/20 | 0.57 |
| ▸ | HDAC9 | Q9UKV0 | 7/20 | 0.57 |
| ▸ | HDAC5 | Q9UQL6 | 7/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | NAMPT | P43490 | 6/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL209583 | 1.00 | HDAC1 (0.58) | HDAC1KCNH2HDAC3HDAC2HDAC4 | |
| SCHEMBL4209055 | 0.90 | HDAC1 (0.73) | HDAC1KCNH2HDAC3HDAC2HDAC4 | |
| SCHEMBL4209044 | 0.90 | HDAC1 (0.73) | HDAC1KCNH2HDAC3HDAC2HDAC4 | |
| SCHEMBL211395 | 0.86 | HDAC1 (0.61) | HDAC1KCNH2HDAC3HDAC2HDAC4 | |
| SCHEMBL211394 | 0.86 | HDAC1 (0.61) | HDAC1KCNH2HDAC3HDAC2HDAC4 | |
| SCHEMBL211459 | 0.86 | HDAC1 (0.60) | HDAC1KCNH2HDAC3HDAC2HDAC4 | |
| SCHEMBL211458 | 0.86 | HDAC1 (0.60) | HDAC1KCNH2HDAC3HDAC2HDAC4 | |
| SCHEMBL212214 | 0.86 | HDAC1 (0.77) | HDAC1KCNH2HDAC3HDAC2HDAC4 | |
| SCHEMBL212213 | 0.86 | HDAC1 (0.77) | HDAC1KCNH2HDAC3HDAC2HDAC4 | |
| SCHEMBL24758125 | 0.85 | HDAC1 (0.59) | HDAC1KCNH2HDAC3HDAC2HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1735319-B1 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE INC (CA) | 2017-05-03 | — | — | EP | disclosed |
| US-8088805-B2 | Inhibitors of histone deacetylase | METHYLGENE INC. (CA) | 2012-01-03 | — | — | US | disclosed |
| US-20070213330-A1 | Anticancer agents; antiproliferative agents | METHYLGENE INC. (CA) | 2007-09-13 | — | — | US | disclosed |
| US-7253204-B2 | Antiproliferative agents | METHYLGENE INC. (CA) | 2007-08-07 | — | — | US | disclosed |
| EP-1735319-A1 | INHIBITORS OF HISTONE DEACETYLASE | Methylgene, Inc. (CA) | 2006-12-27 | — | — | EP | disclosed |
| US-20050245518-A1 | Antiproliferative agents | METHYLGENE, INC. | 2005-11-03 | — | — | US | disclosed |
| WO-2005092899-A1 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE INC. (CA) | 2005-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213330-A1 | Anticancer agents; antiproliferative agents | HDAC1, HDAC11, HDAC5 | HDAC1 1/4885KCNH2 4286/4885HDAC3 4/4885 |
| US-20050245518-A1 | Antiproliferative agents | HDAC1, HDAC11, HDAC5 | HDAC1 1/4885KCNH2 4402/4885HDAC3 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.